Abstracts tagged "Women’s health"

Abstract Number: 0794 • ACR Convergence 2025
Using Artificial Intelligence to Analyze Multilingual Qualitative Data in Lupus Pregnancy Research: A Proof of Concept with Large Language Models
Romina Boers¹, Grace Terry² and Bella Mehta³, ¹Weil Cornell Medicine, New York, ²Weil Cornell Medicine, Ne wYork, ³Hospital for Special Surgery, Weill Cornell Medicine, Jersey City, NJ
Background/Purpose: Women with systemic lupus erythematosus (SLE), particularly those of childbearing age, face heightened risks during pregnancy, including disease flares, adverse maternal-fetal outcomes, and emotional…
Abstract Number: 2575 • ACR Convergence 2025
Influenza and COVID-19 Vaccination Uptake Among Women with Systemic Rheumatic Diseases in New York City Assessed Between 2022 and 2024
Yongjay Kim¹, Sandhya Kannayiram², Amaya Smole³, Lucy Masto⁴, Neha Nagpal⁵, Naiva Manuela Piatchou Donfack⁵, Deanna Jannat-Khah⁵, Lisa Mandl⁵, Caroline Siegel⁵, Sarah Lieber⁵, Michael Lockshin⁵, Lisa Sammaritano⁵ and Medha Barbhaiya⁵, ¹Hospital for Special Surgery, Englewood Cliffs, NJ, ²Hospital for Special Surgery, Weill Cornell Medicine, New York, ³Hospital for Special Surgery, Brooklyn, NY, ⁴Hospital for Special Surgery, San Francisco, CA, ⁵Hospital for Special Surgery, New York, NY
Background/Purpose: Women with systemic rheumatic diseases (SRDs), and particularly those on immunosuppressive medications, are at increased risk for serious infections such as influenza and COVID-19.…
Abstract Number: 2200 • ACR Convergence 2025
Obstetric and Neonatal Complications in Women living with Axial Spondyloarthritis: a population-based, matched cohort study
Sinead Maguire¹, John Snelgrove², Priscila Pequeno³, Michael Paterson⁴, Fangyun Wu⁴, Laura Passalent⁵, Anthony Perruccio⁶, Dharini Mahendira⁷, Elie Karam⁸, Robert Inman⁹ and Nigil Haroon¹⁰, ¹Our Lady's Hospital Navan, Dublin, Dublin, Ireland, ²Mount Sinai Hospital, Toronto, Canada, ³Institute for Clinical Evaluative Sciences (ICES), Toronto, Canada, ⁴Institute of Clinical & Evaluative Sciences, Toronto, Canada, ⁵Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada, ⁶Schroeder Arthritis Institute and Krembil Research Institute, University Health Network, Toronto, Canada, ⁷St Michael's Hospital, Toronto, Canada, ⁸Canadian Spondylitis Association, Toronto, Canada, ⁹University Health Network, Toronto, ON, Canada, ¹⁰Department of Medicine/Rheumatology, University Health Network, Schroeder Arthritis Institute, University of Toronto, Toronto, ON, Canada
Background/Purpose: Women with axial spondyloarthritis (axSpA) are frequently diagnosed during their childbearing years. While studies have reported on pregnancy complications in this population, deriving generalizable…
Abstract Number: 0755 • ACR Convergence 2025
Sex Differences in Subtypes of Vascular Involvement and Clinical Manifestations in Giant Cell Arteritis
Natalia Lopez Juanes, Carlota Ureta, Irene Monjo Henry, Maria-Eugenia Miranda-Carus, Chamaida Plasencia-Rodríguez and Eugenio de Miguel, Hospital Universitario La Paz, Madrid, Spain
Background/Purpose: Recognizing gender-specific differences in diseases is critical to improve diagnostic and therapeutic strategies. Giant cell arteritis (GCA) has been traditionally considered a predominantly female…
Abstract Number: 2565 • ACR Convergence 2025
Assessing Participation in the Lupus Sister Circle Support Group
Khadija Dantata, Wendy Rodgers and Lety Ocana, The Lupus Foundation of America, Washington, DC
Background/Purpose: Relative to White people with lupus (PWL), Black/African American (B/AA) PWL are three times as likely to develop lupus and suffer a severe form…
Abstract Number: 2197 • ACR Convergence 2025
Mechanisms of Fetal Growth Restriction in Rheumatologic Autoimmune Diseases: Insights into Placental Pathology and Immune Dysregulation
Larabe Farrukh¹, Ananya Venkatesh², Mana Parast² and Chelsey Smith³, ¹University of California San Diego, San Diego, CA, ²University of California San Diego, San Diego, ³University of California San Diego, LA JOLLA, CA
Background/Purpose: Fetal growth restriction (FGR) significantly contributes to adverse pregnancy outcomes (APOs) in women with rheumatologic diseases. Understanding the immunopathologic mechanisms underlying FGR is critical…
Abstract Number: 0465 • ACR Convergence 2025
Reproductive Factors and Risk of Rheumatoid Arthritis-Associated Interstitial Lung Disease or Bronchiectasis in Women
Suchita Nety¹, Xiaosong Wang², Misti Paudel³, Ying Qi⁴, Qianru Zhang¹, Nancy Shadick⁵, Michael Weinblatt⁶, Liya Sisay Getachew⁷, Gregory McDermott⁸ and Jeffrey Sparks⁷, ¹Harvard Medical School, Boston, MA, ²Brigham and Women's Hospital, Natick, MA, ³Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ⁴Brigham and Women’s Hospital, Boston, ⁵Brigham & Women's Hospital, Boston, MA, ⁶Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, ⁷Brigham and Women's Hospital, Boston, MA, ⁸Brigham and Women's Hospital, Brookline, MA
Background/Purpose: RA-associated lung diseases (RA-LD) such as RA-associated interstitial lung disease (RA-ILD) and RA-associated bronchiectasis (RA-BR) are more common in men, but risk rises with…
Abstract Number: 2395 • ACR Convergence 2025
Analysis of histopathological changes in the placenta of patients with systemic lupus erythematosus
Bartira Melo¹, Elizabeth Avvad², Marcela lacerda², Nilson jesus², Evandro Klumb² and Guilherme Ramires de Jesus³, ¹UERJ- Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ²UERJ - Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ³Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Rio de Janeiro, Brazil
Background/Purpose: Systemic lupus erythematosus (SLE) is more frequent in women of reproductive age and pregnancy in these patients is considered as high risk. The inflammatory…
Abstract Number: 2196 • ACR Convergence 2025
Recognition and Treatment of Idiopathic Granulomatous Mastitis: A Case Series
Jenny Solomon¹, Julie Piccione¹, Julie Nusbaum², Steven Carsons³ and Gregg Blumberg¹, ¹NYU Langone Long Island, Mineola, ²NYU Langone Health, New York, NY, ³NYU Long Island School of Medicine, Mineola, NY
Background/Purpose: Idiopathic Granulomatous Mastitis (IGM) is a rare benign inflammatory condition of the breast usually affecting women of childbearing age with a history of breastfeeding.…
Abstract Number: 0460 • ACR Convergence 2025
The Impact of Early and Artificial Menopause on Dementia Risk Among Women with Rheumatoid Arthritis
Ryan Salama¹, Cassondra Hulshizer², Cynthia Crowson³ and Elena myasoedova¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, ³Mayo Clinic, Stewartvillle, MN
Background/Purpose: Alzheimer’s disease and related dementias present an increasing global health concern, with increasing incidence and prevalence. Hormonal fluctuations associated with menopause may exacerbate inflammatory…
Abstract Number: 2316 • ACR Convergence 2025
Sexual Dysfunction in Women with Axial Spondyloarthritis: A Meta-Analysis of FSFI Total and Domain Scores
Gabriela Moreira¹, Hemerli De Cinque Almeida Esteves², Nicole Felix³ and Jose Fernando Verztman¹, ¹Hospital Federal dos Servidores do Estado do Rio de Janeiro, Rio de Janeiro, Rio de Janeiro, Brazil, ²No current affiliation, Columbus, OH, ³Federal University of Campina Grande, Fortaleza, Ceara, Brazil
Background/Purpose: Beyond musculoskeletal manifestations, there is growing recognition of the systemic and psychosocial burden of axial spondyloarthritis (axSpA). Sexual health is an often-overlooked aspect of…
Abstract Number: 2195 • ACR Convergence 2025
Enhancing MTX and LEF Safety for Immunosuppressed Women of Childbearing Age with Rheumatic Diseases
Angela Bobak¹, Rhea Sharma², Jordan Jackson³, Maritza Nary², Andrea Berger⁴, Lifang Zhang⁴ and Jonida Cote⁵, ¹Geisinger Medical Center Rheumatology Fellowship, Danville, PA, ²Geisinger Medical Center Internal Medicine Residency, Danville, PA, ³Geisinger Medical Center Medicine-Pediatrics Residency, Danville, PA, ⁴Geisinger Health System, Danville, PA, ⁵Geisinger Health System, Wilkes-Barre, PA
Background/Purpose: The rates of contraceptive counseling and treatment in immunosuppressed women of childbearing age remain low in the United States, despite ACR's Reproductive Health Guidelines…
Abstract Number: 0451 • ACR Convergence 2025
Menopause Status and Disease Activity in Rheumatoid Arthritis
Katherine Bracamontes¹, David Kellner², Lucia Chen³, David Elashoff⁴, Jenny Brook⁵ and Veena Ranganath², ¹Division of Internal Medicine, UCLA, Los Angeles, CA, ²UCLA, Los Angeles, CA, ³UCLA, Division of General Internal Medicine and Health Services Research, Los Angeles, CA, ⁴UCLA, Division of General Internal Medicine and Health Services Research, Los Angeles, ⁵UCLA, Division of General Internal Medicine and Health Services Research, Los Angeles, CA
Background/Purpose: In women, rheumatoid arthritis (RA) commonly presents around menopause, a timing thought to be influenced by the decline of estrogen and progesterone. However, the…
Abstract Number: 0134 • ACR Convergence 2024
Use of Oral Contraceptives in Females with Rheumatoid Arthritis Is Not Associated with an Increased Risk of Venous Thromboembolism: United Kingdom-population Based Study
James Galloway¹, Victoria Basey², Anna Barkaway³, Simon de Lusignan⁴ and Maya H. Buch⁵, ¹Centre for Rheumatic Diseases, King's College London, London, United Kingdom, ²Pfizer UK, Tadworth, United Kingdom, ³Pfizer, Tadworth, United Kingdom, ⁴Royal College of General Practitioners Research and Surveillance Centre, Oxford, United Kingdom, ⁵Division of Musculoskeletal & Dermatological Sciences, University of Manchester, and NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom
Background/Purpose: While the use of oral contraceptives in females with immune mediated inflammatory diseases such as rheumatoid arthritis (RA) is acknowledged as a risk factor…
Abstract Number: 0434 • ACR Convergence 2024
Pregnancy Outcomes of Biosimilars and Non-TNF Inhibitor Biologic Disease-Modifying Antirheumatic Drugs: A Scoping Review
Vienna Cheng¹, Neda Amiri², Vicki Cheng¹, Ursula Ellis³, Jacquelyn J. Cragg¹, Mark Harrison¹ and Mary A. De Vera¹, ¹University of British Columbia, Faculty of Pharmaceutical Sciences, Vancouver, BC, Canada, ²University of British Columbia, Faculty of Medicine, Vancouver, BC, Canada, ³University of British Columbia, Woodward Library, Vancouver, BC, Canada
Background/Purpose: Biosimilar and biologic (b) DMARDs have revolutionized rheumatic disease management in the recent decades. As these drugs become introduced, it is important to understand…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].